Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.43 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | EED | O75530 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3430852 | 0.89 | MTNR1A (0.62) | KDM4CMTNR1APTGER1PTGER4PTGER3 | |
| SCHEMBL9160573 | 0.88 | MTNR1A (0.56) | KDM4CMTNR1AFAAHMAPT | |
| SCHEMBL28567024 | 0.85 | MTNR1A (0.48) | KDM4CMTNR1AFAAHALKBH1ALDH1A1 | |
| SCHEMBL9251696 | 0.85 | MTNR1A (0.51) | KDM4CMTNR1AFAAHALKBH1ALDH1A1 | |
| SCHEMBL3402977 | 0.83 | KDM4C (0.50) | KDM4CMTNR1AFAAHALKBH1ALDH1A1 | |
| SCHEMBL8946082 | 0.81 | PTGER1 (0.46) | MTNR1APARP1PTGER1PTGER4PTGER3 | |
| SCHEMBL11957288 | 0.80 | MTNR1A (0.52) | KDM4CMTNR1AFAAHALDH1A1MEN1 | |
| SCHEMBL6649870 | 0.80 | MTNR1A (0.71) | MTNR1AMEN1KMT2AMAPK1KDM4E | |
| SCHEMBL4130192 | 0.79 | KDM4C (0.46) | KDM4CMTNR1AFAAHALDH1A1EED | |
| SCHEMBL7771835 | 0.79 | KDM4C (0.46) | KDM4CMTNR1AFAAHALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252957-A1 | PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS | ELAN PHARMACEUTICALS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252957-A1 | PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS | ELAN PHARMACEUTICALS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252957-A1 | PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS | ELAN PHARMACEUTICALS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-8487121-B2 | Chromane derivatives as TRPV3 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-07-16 | — | — | US | disclosed |
| CN-103183660-A | Chromane derivative used as TRPV3 (transient receptor potential vanilloid 3) conditioning agent | GLENMARK PHARMACEUTICALS SA | 2013-07-03 | — | — | CN | disclosed |
| US-8367836-B2 | Pyridinone antagonists of alpha-4 integrins | ELAN PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367836-B2 | Pyridinone antagonists of alpha-4 integrins | ELAN PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367836-B2 | Pyridinone antagonists of alpha-4 integrins | ELAN PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| CN-102459179-A | Pyridinone antagonists of alpha-4 integrins | ELAN PHARM INC | 2012-05-16 | — | — | CN | disclosed |
| EP-2424841-A1 | PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS | Elan Pharmaceuticals Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20110009407-A1 | PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS | ELAN PHARMACEUTICALS, INC. | 2011-01-13 | — | — | US | disclosed |
| US-20110009407-A1 | PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS | ELAN PHARMACEUTICALS, INC. | 2011-01-13 | — | — | US | disclosed |
| US-20110009407-A1 | PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS | ELAN PHARMACEUTICALS, INC. | 2011-01-13 | — | — | US | disclosed |
| US-20100311778-A1 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-12-09 | — | — | US | disclosed |
| EP-2254879-A2 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2010-12-01 | — | — | EP | disclosed |
| WO-2010126914-A1 | PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS | ELAN PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010126914-A1 | PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS | ELAN PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2009084034-A2 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS, S. A. (CH) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311778-A1 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | TRPV3, TRPV2, TRPV1 | KDM4C 3874/4885MTNR1A 187/4885FAAH 1303/4885 |
| US-20130252957-A1 | PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS | ITGA4, ITGB4, ITGB5 | KDM4C 671/4885MTNR1A 163/4885FAAH 4804/4885 |
| US-20110009407-A1 | PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS | ITGA4, ITGB4, ITGB5 | KDM4C 671/4885MTNR1A 163/4885FAAH 4804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.